Repatha (evolocumab) will be sold in the UK at a cost of $6,780 per year, less than half the $14,100 Amgen is charging for the drug in the US, with the price in other EU markets typically below ...

A federal jury in Delaware put US biotech major Amgen (Nasdaq: AMGN) on the hook Thursday for at least $271.2 million in ...

to select Repatha® (evolocumab) as the exclusive PCSK9 category product over Praluent® (alirocumab). The jury found that Amgen violated the Clayton Act, the Sherman Act, the New York State ...

to select Repatha (evolocumab) as the exclusive PCSK9 category product over Praluent (alirocumab). The jury found that Amgen violated the Clayton Act, the Sherman Act, the New York State Donnelly ...

Coming back to the first-quarter results, sales of most of its products, like Prolia, Xgeva, Repatha, Blincyto and Evenity, beat estimates. Fourteen products, including Repatha, Blincyto ...

Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

Amgen threatened to withhold rebates unless PBMs preferred Repatha and excluded Praluent. Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to ...